A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants
An Open-Label, Randomized, 3-Way Crossover Study Comparing the Pharmacokinetics of Multiple Olomorasib (LY3537982) Capsules
Sponsor: Eli Lilly and Company
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Time Zero to Time t (AUC[0-tlast]) of Olomorasib
Time frame: From Day 1, Predose up to 72 hours Postdose
PK: Area Under the Concentration versus Time Curve from Zero to Infinity (AUC[0-∞]) of Olomorasib
Time frame: From Day 1, Predose up to 72 hours Postdose
PK: Maximum Observed Drug Concentration (Cmax) of Olomorasib
Time frame: From Day 1, Predose up to 72 hours Postdose
Eligibility Criteria
Inclusion Criteria: * Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease * Body mass index (BMI): 18.0 to 30.0 kilograms per square meter (kg/m²), inclusive * Participants assigned male at birth (AMAB) or assigned female at birth (AFAB) who are individuals not of childbearing potential (INOCBP). Exclusion Criteria: * Females who are lactating or of childbearing potential * Clinically significant history of any drug sensitivity, drug allergy, or food allergy * Have used or plan to use medication within 14 days or 5 half-lives, whichever is longest, prior to admission, with the exception occasional acetaminophen at doses less than or equal to 2 g/day.
✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →